Group Mailing 2025-01-01

Priority Lists

Disease Committee	Last Changed
Breast Cancer	3/6/26
Cancer Care Delivery	8/4/25
comboMATCH	10/16/25
Early Therapeutics & Rare Cancers	11/7/25
Gastrointestinal Cancer	12/30/25
Genitourinary Cancer	1/19/26
Head and Neck Cancer	10/16/25
iMATCH	12/3/25
Immunomolecular Therapeutics	12/3/25
Leukemia	12/30/25
Lung Cancer	9/8/25
LungMAP	4/24/25
Lymphoma	10/23/25
Melanoma	11/7/25
Myeloma	10/23/25
myeloMATCH	12/30/25
Other	2/1/14
Palliative Care	10/24/25
Prevention, Screening, and Surveillance	1/1/25
Sarcoma	9/15/07
SWOG CTP	10/16/25
Symptom Management and Survivorship	10/24/25

Scroll Table

Activations

Closures

S1803Phase III Intergroup

Partial Permanent Closure - Effective Date 1/15/2025

Phase III Study of Daratumumab (NSC- 791647) + Lenalidomide (LD) or Lenalidomide (L) as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)

Action Codes	ER
Study Coordinator(s)	Amrita Krishnan, M.D.
Participants	ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS

S2010Phase III

Permanent Closure to Accrual - Effective Date 1/15/2024

A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone To Improve Persistence with Endocrine Therapy in Young Women With Stage I-III Breast Cancer (ASPEN)

Action Codes	NR
Study Coordinator(s)	Norah L. Henry, M.D.,Ph.D., Dawn Hershman, M.D., M.S.

Amendments, Revisions, Memoranda

Other New Items

IP - Pts Must Be Informed
AC - Consent Must Be Amended
CBR - No Registration Allowed until IRB Review
RC - Formal Re-consent Required
FBR - Full Board Review Required
ER - Expedited Review Acceptable
NR - No IRB Review Required

Trial & Business Updates: 1/1/2025